Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
a-MANTRA: Maintenance Regorafenib vs Placebo After First-line Chemotherapy in HER2-negative Advanced Gastric/GEJ Cancer
2016-003031-38Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Regorafenib maintenance with Placebo maintenance (2 arms). Primary endpoints: Progression Free Survival 1 (PFS1) and Progression Free Survival (PFS) in all randomized patients. Started Jan 2021; status: completed.
02
Drugs
regorafenib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2016-003031-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003031-38.